Clinical Trials Browser

Phase 3 × OTHER × tislelizumab × Clear all

NCT07475026 2026-03-16

A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

Phase 3 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07373990 2026-01-28

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

Nasopharyngeal Neoplasms

NCT06914011 2025-12-03

MRD2START

Phase 3 Not yet recruiting

Gastrointestinal

Esophageal Neoplasms

NCT07132008 2025-08-20

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

Phase 3 Not yet recruiting

Gastrointestinal

Colonic Neoplasms

NCT07068516 2025-07-16

Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer

Phase 3 Not yet recruiting

Gastrointestinal

Gastric Cancer Stage

NCT06939439 2025-07-01

Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer

Phase 3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT06598527 2025-05-29

SACTION2401

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06332274 2025-05-13

UMBRELLA

Phase 3 Recruiting

GastrointestinalSarcomaThoracic

Colonic Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT06258811 2025-03-13

Neoadjuvant Immunochemotherapy for LAOSCC

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06364904 2025-02-21

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Phase 3 Not yet recruiting

Urinary Bladder Neoplasms

NCT06704620 2024-12-16

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05919030 2024-11-14

A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma

Phase 3 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06520683 2024-11-07

SMALLER

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06383780 2024-07-16

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT06441110 2024-06-04

Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Phase 3 Recruiting

Urinary Bladder Neoplasms, Motor Activity, Neoplasm Recurrence, Local

NCT05211232 2024-04-18

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT06017583 2023-10-11

Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer

Phase 3 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06031597 2023-09-13

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung, Radiation Pneumonitis

NCT05342792 2022-04-25

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Phase 3 Recruiting

Nasopharyngeal Carcinoma